Literature DB >> 25007959

Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells.

Yifang Wei1, Xiaofeng Lai, Shentong Yu, Suning Chen, Yongzheng Ma, Yuan Zhang, Huichen Li, Xingmei Zhu, Libo Yao, Jian Zhang.   

Abstract

Recent studies have demonstrated that specific miRNAs, such as miR-221/222, may be responsible for tamoxifen resistance in breast cancer. Secreted miRNAs enclosed in exosomes can act as intercellular bio-messengers. Our objective is to investigate the role of secreted miR-221/222 in tamoxifen resistance of ER-positive breast cancer cells. Transmission electron microscopy analysis and nanoparticle tracking analysis were performed to determine the exosomes difference between MCF-7(TamR) (tamoxifen resistant) and MCF-7(wt) (tamoxifen sensitive) cells. PKH67 fluorescent labeling assay was used to detect exosomes derived from MCF-7(TamR) cells entering into MCF-7(wt) cells. The potential function of exosomes on tamoxifen resistance transmission was analyzed with cell viability, apoptosis ,and colony formation. MiRNA microarrays and qPCR were used to detect and compare the miRNAs expression levels in the two cells and exosomes. As the targets of miR-221/222, p27 and ERα were analyzed with western blot and qPCR. Compared with the MCF-7(wt) exosomes, there were significant differences in the concentration and size distribution of MCF-7(TamR) exosomes. MCF-7(wt) cells had an increased amount of exosomal RNA and proteins compared with MCF-7(TamR) cells. MCF-7(TamR) exosomes could enter into MCF-7(wt) cells, and then released miR-221/222. And the elevated miR-221/222 effectively reduced the target genes expression of P27 and ERα, which enhanced tamoxifen resistance in recipient cells. Our results are the first to show that secreted miR-221/222 serves as signaling molecules to mediate communication of tamoxifen resistance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25007959     DOI: 10.1007/s10549-014-3037-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  122 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

Review 2.  Extracellular vesicles in breast cancer drug resistance and their clinical application.

Authors:  Shentong Yu; Yifang Wei; Yuqiao Xu; Yuan Zhang; Jipeng Li; Jian Zhang
Journal:  Tumour Biol       Date:  2016-01-21

Review 3.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

Review 4.  Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes.

Authors:  Valentina R Minciacchi; Michael R Freeman; Dolores Di Vizio
Journal:  Semin Cell Dev Biol       Date:  2015-02-23       Impact factor: 7.727

5.  Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype.

Authors:  Sanket H Shah; Philip Miller; Marta Garcia-Contreras; Zheng Ao; Leah Machlin; Emilio Issa; Dorraya El-Ashry
Journal:  Cancer Biol Ther       Date:  2015-07-17       Impact factor: 4.742

6.  Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.

Authors:  Martin Porsch; Esra Özdemir; Martin Wisniewski; Sebastian Graf; Fabian Bull; Katrin Hoffmann; Atanas Ignatov; Johannes Haybaeck; Ivo Grosse; Thomas Kalinski; Norbert Nass
Journal:  RNA Biol       Date:  2019-03-05       Impact factor: 4.652

Review 7.  Insights into the key roles of proteoglycans in breast cancer biology and translational medicine.

Authors:  Achilleas D Theocharis; Spyros S Skandalis; Thomas Neill; Hinke A B Multhaupt; Mario Hubo; Helena Frey; Sandeep Gopal; Angélica Gomes; Nikos Afratis; Hooi Ching Lim; John R Couchman; Jorge Filmus; Ralph D Sanderson; Liliana Schaefer; Renato V Iozzo; Nikos K Karamanos
Journal:  Biochim Biophys Acta       Date:  2015-03-28

8.  Exosome-mediated drug resistance in cancer: the near future is here.

Authors:  Marco Giallombardo; Simona Taverna; Riccardo Alessandro; David Hong; Christian Rolfo
Journal:  Ther Adv Med Oncol       Date:  2016-05-12       Impact factor: 8.168

Review 9.  The novel role of miRNAs for tamoxifen resistance in human breast cancer.

Authors:  Wenwen Zhang; Jing Xu; Yaqin Shi; Qian Sun; Qun Zhang; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2015-03-18       Impact factor: 9.261

10.  Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels.

Authors:  Nina Petrovic; Radoslav Davidovic; Snezana Jovanovic-Cupic; Milena Krajnovic; Silvana Lukic; Milan Petrovic; Jelena Roganovic
Journal:  Mol Diagn Ther       Date:  2016-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.